Rational Design and Preclinical Evaluation of LRP1-Targeted 68Ga-Labeled Angiopep-2 Peptides for PET Imaging of Hepatocellular Carcinoma
Molecular Pharmaceutics · 06.11.2026
DOI: 10.1021/acs.molpharmaceut.6c00933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 06.11.2026. Verfasst von Xinyue Du und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Key Programme, China Postdoctoral Science Foundation, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a heterogeneous malignancy lacking effective strategies for subtype-specific molecular imaging. Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional receptor implicated in HCC progression. Herein, we report the rational design and systematic comparison of three Angiopep-2-derived 68Ga-labeled radiotracers with distinct DOTA conjugation positions, aiming to elucidate how chelator placement modulates targeting specificity and in vivo imaging contrast for LRP1-positive HCC. Immunohistochemical analysis of an HCC tissue microarray confirmed LRP1 overexpression in 19.3% of clinical specimens, which correlated with poorer overall survival and defined a high-risk subgroup. All tracers exhibited high radiochemical purity, excellent stability, and favorable pharmacokinetic profiles. In vitro, 68Ga-DOTA-ANG-2 and 68Ga-DOTA-ANG-3 showed robust uptake in LRP1-high Huh-7 cells. Although 68Ga-DOTA-ANG-2 achieved the highest absolute tumor uptake, 68Ga-DOTA-ANG-3 demonstrated markedly reduced nonspecific hepatic accumulation, yielding a superior tumor-to-liver contrast (5.61 ± 1.33 at 120 min). MicroPET/CT imaging in subcutaneous and orthotopic HCC models verified that 68Ga-DOTA-ANG-3 enables sensitive and high-contrast detection of intrahepatic lesions. Collectively, 68Ga-DOTA-ANG-3 is a promising positron emission tomography (PET) agent for subtype-specific HCC imaging, supporting further evaluation of LRP1-targeted PET imaging in a biomarker-defined subset of HCC.
Förderung
- Key Programme
- China Postdoctoral Science Foundation
- Science and Technology Commission of Shanghai Municipality
- Shanghai Oriental Talents Program Youth Project
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Du, X., Sun, L., Liu, W., Lu, X., Zhang, J., He, S., Xu, X., & Song, S. (2026). Rational Design and Preclinical Evaluation of LRP1-Targeted 68Ga-Labeled Angiopep-2 Peptides for PET Imaging of Hepatocellular Carcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00933
Vancouver
Du X, Sun L, Liu W, Lu X, Zhang J, He S, et al. Rational Design and Preclinical Evaluation of LRP1-Targeted 68Ga-Labeled Angiopep-2 Peptides for PET Imaging of Hepatocellular Carcinoma. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00933
BibTeX
@article{Du2026,
author = {Du, Xinyue and Sun, Li and Liu, Wendi and Lu, Xin and Zhang, Jianping and He, Simin and Xu, Xiaoping and Song, Shaoli},
title = {Rational Design and Preclinical Evaluation of LRP1-Targeted 68Ga-Labeled Angiopep-2 Peptides for PET Imaging of Hepatocellular Carcinoma},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00933}
}
EUVIMED